Home Cart Sign in  
Chemical Structure| 921605-87-0 Chemical Structure| 921605-87-0

Structure of MF-438
CAS No.: 921605-87-0

Chemical Structure| 921605-87-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MF-438 is an inhibitor of stearoyl-CoA desaturase 1 (SCD1) with EC50 of 2.3 nM for rSCD1.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MF-438

CAS No. :921605-87-0
Formula : C19H18F3N5OS
M.W : 421.44
SMILES Code : FC(C1=CC=CC=C1OC2CCN(C3=NN=C(C4=NN=C(C)S4)C=C3)CC2)(F)F
MDL No. :MFCD28386313
InChI Key :NVUJDKDVOZVALT-UHFFFAOYSA-N
Pubchem ID :16042458

Safety of MF-438

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of MF-438

ferroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mel 66 0.007–50μM 7 days Evaluate the anti-tumor activity of MF-438 on Mel 66 cells, showing that MF-438 can inhibit cell proliferation and reduce sphere-forming efficiency. J Exp Clin Cancer Res. 2018 Dec 17;37(1):318
M14 0.007–50μM 7 days Evaluate the anti-tumor activity of MF-438 on M14 cells, showing that MF-438 can inhibit cell proliferation and reduce sphere-forming efficiency. J Exp Clin Cancer Res. 2018 Dec 17;37(1):318
A375 0.007–50μM 7 days Evaluate the anti-tumor activity of MF-438 on A375 cells, showing that MF-438 can inhibit cell proliferation and reduce sphere-forming efficiency. J Exp Clin Cancer Res. 2018 Dec 17;37(1):318
HT-29 0.06 µM 72 hours Inhibition of HT-29 cell growth, IC50 at 0.06 µM Int J Mol Sci. 2025 Jan 30;26(3):1186
SHEE 0.25 μM 24 hours To evaluate the effect of MF-438 on the viability of SHEE cells, results showed that MF-438 had no significant toxicity on normal cells. Oncoimmunology. 2022 Jul 15;11(1):2101769
KYSE410 0.25 μM 24 hours To evaluate the effect of MF-438 on the viability of KYSE410 cells, results showed that MF-438 significantly reduced cell viability. Oncoimmunology. 2022 Jul 15;11(1):2101769
KYSE70 0.25 μM 24 hours To evaluate the effect of MF-438 on the viability of KYSE70 cells, results showed that MF-438 significantly reduced cell viability. Oncoimmunology. 2022 Jul 15;11(1):2101769
M17D neuroblastoma cells 1 μM 96 hours To test whether MF-438 could rescue αS-3K::YFP-induced cytotoxicity, results showed that MF-438 fully restored cell growth without apparent cytotoxicity. Int J Mol Sci. 2020 Jul 22;21(15):5193
human peripheral blood monocytes 1 µmol/mL 7 days To evaluate the effect of MF-438 on the transformation of monocytes into macrophages, results showed that MF-438 significantly reduced the number of macrophages and the concentration of SCD1. J Inflamm Res. 2022 Feb 8;15:793-806

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID mice Esophageal squamous cell carcinoma model Oral 800 μg/kg Once a day for 2 weeks To evaluate the therapeutic effect of MF-438 on esophageal squamous cell carcinoma in vivo, results showed that MF-438 significantly inhibited tumor growth. Oncoimmunology. 2022 Jul 15;11(1):2101769
Wistar rats Pregnant rat model Oral gavage 5 mg/kg/day Once daily for 5 days To evaluate the influence of early oleate deficiency on fetal rat liver development. Results showed that MF-438 treatment led to significant reductions in morphological indices and hepatic maturation markers in fetal livers, while MF-438 plus oleate treatment increased total hepatic protein and glycogen content and significantly upregulated the expression of hepatocyte nuclear factor 1α, alpha fetoprotein, albumin, and cytochrome P450 genes. Iran J Basic Med Sci. 2019 Sep;22(9):1010-1015

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.37mL

0.47mL

0.24mL

11.86mL

2.37mL

1.19mL

23.73mL

4.75mL

2.37mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories